CO News and Press, Global Cord Blood Corporation From 02/15/22

The shares of medical technology stock Senseonics Holdings (SENS) dipped marginally in price yesterday, despite the company receiving FDA approval for its Eversense E3 glucose monitoring system. So, with unsustainable valuations and a bleak earnings outlook, will SENS'stock be able to regain ...

Diabetes-focused medical company Senseonics (SENS) reported top- and bottom-line growth in its last reported quarter. But is it wise to bet on the stock now despite the intense competition it faces? Read on to learn our view. Medical technology company Senseonics Holdings, Inc. ( SENS ...

Cell-based therapies developer MaxCyte (MXCT) made a stellar stock market debut in July last year. However, the stock has lost more than 30% since then, closing yesterday’s trading session at $10.84. With poor financials and profit margins, will MXCT recover this year? Read more to fin...

Global Cord Blood (NYSE:CO) has rejected a $5/share proposal from Alternate Ocean Investment, a wholly-owned subsidiary of Haitong International Securities (OTCPK:HTNGF). Global's board said the offer "fails to properly reflect the value of the Company and maximize shareholder value." Global ...

Global Cord Blood Corporation Announces Rejection of Alternate Ocean Proposal PR Newswire HONG KONG , Dec. 16, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laborato...

Global Cord Blood Corporation Announces Results of 2021 Annual General Meeting PR Newswire HONG KONG , Dec. 7, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, ...

Revenues increased 10% this quarter. The company grew in subscribers count this quarter and this was a positive sign. 24% EPS 5-year CAGR, which points to the company’s ability to maintain secular growth. 203% net cash to the market cap. 6.0x P/E makes CO very under...

The diagnostics & research industry is booming due to the resurgence of COVID-19 cases and increasing chronic disease sufferers. However, not all industry participants are well-positioned to gain in the near term. For instance, we think iSpecimen (ISPC) looks overvalued at the current pri...

Image source: The Motley Fool. Global Cord Blood Corporation (NYSE: CO) Q2 2022 Earnings Call Nov 26, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Global Cord Blood Corporation (CO) Q2 2022 Earnings Call Transcri...

Global Cord Blood Corporation (CO) Q2 2022 Earnings Conference Call November 26, 2021, 08:00 AM ET Company Participants Cathy Bai - VP of Corporate Finance Albert Chen - CFO Conference Call Participants Jeff Oliver - Star Funds Presentation Operator Welcome everyone to Global Cord Blood Corpo...